Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for ...

Application error: a client-side exception has occurred (see the browser console for more information).

Berlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended darolutamide, an oral androgen receptor ...

ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing ...

Hormone therapy for prostate cancer is aimed at reducing or eliminating the amount of testosterone in your body to slow or stop prostate cancer cells from growing and multiplying. Hormone therapy ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ...

EMA committee recommends marketing approval for Bayer’s Nubeqa for patients with advanced prostate cancer: Berlin Saturday, June 21, 2025, 10:00 Hrs [IST] The Committee for Medi ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Cancer Research UK-funded scientists at the University of Cambridge create a test to predict resistance to chemotherapy. The test uses changes to cancer DNA at diagnosis to predict which patients will ...

MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab ...

ASCO 2025 IRONMAN: Can PSA Guide Metastatic Prostate Cancer Care? New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for treatment ...